An ADAR1-dependent RNA editing event in the cyclin-dependent kinase CDK13 promotes thyroid cancer hallmarks

被引：0
|
作者：
Julia Ramírez-Moya
Christos Miliotis
Allison R. Baker
Richard I. Gregory
Frank J. Slack
Pilar Santisteban
机构：
[1] Universidad Autónoma de Madrid (UAM),Instituto, de Investigaciones Biomédicas “Alberto Sols”; Consejo Superior de Investigaciones Científicas (CSIC)
[2] Harvard Medical School,Department of Pathology, Harvard Medical School Initiative for RNA Medicine, Beth Israel Deaconess Medical Center
[3] Harvard Medical School Initiative for RNA Medicine,Stem Cell Program, Division of Hematology/Oncology, Boston Children’s Hospital, Departments of Biological Chemistry and Molecular Pharmacology, and Pediatrics, Harvard Medical School
[4] Centro de Investigación Biomédica en Red de Cáncer (CIBERONC) Instituto de Salud Carlos III (ISCIII),undefined
来源：
Molecular Cancer | / 20卷
关键词：
ADAR1; A-to-I editing; Cancer; CDK13; Splicing;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 50 条
  • [21] Targeting cyclin-dependent kinase 1 (CDK1) in cancer: molecular docking and dynamic simulations of potential CDK1 inhibitors
    Sofi, Shazia
    Mehraj, Umar
    Qayoom, Hina
    Aisha, Shariqa
    Almilaibary, Abdullah
    Alkhanani, Mustfa
    Mir, Manzoor Ahmad
    MEDICAL ONCOLOGY, 2022, 39 (09)
  • [22] Signaling of cyclin-dependent kinase 12 (CDK12) in prostate cancer cell lines
    Chalfant, Victor
    Riveros, Carlos
    Shukla, Sanjeev
    Osumi, Teruko
    Balaji, K.
    CANCER RESEARCH, 2022, 82 (12)
  • [23] miR-592 acts as an oncogene and promotes medullary thyroid cancer tumorigenesis by targeting cyclin-dependent kinase 8
    Liu, Ting
    Meng, Jingjing
    Zhang, Yu
    MOLECULAR MEDICINE REPORTS, 2020, 22 (04) : 3316 - 3326
  • [24] ik3-1/Cables is a substrate for cyclin-dependent kinase 3 (cdk 3)
    Yamochi, T
    Semba, K
    Tsuji, K
    Mizumoto, K
    Sato, H
    Matsuura, Y
    Nishimoto, I
    Matsuoka, M
    EUROPEAN JOURNAL OF BIOCHEMISTRY, 2001, 268 (23): : 6076 - 6082
  • [25] The cyclin-dependent kinase pathway involving CDK1 is a potential therapeutic target for cholangiocarcinoma
    Yamamura, Minako
    Sato, Yasunori
    Takahashi, Kenta
    Sasaki, Motoko
    Harada, Kenichi
    ONCOLOGY REPORTS, 2020, 43 (01) : 306 - 317
  • [26] Targeting cyclin-dependent kinase 1 (CDK1) but not CDK4/6 or CDK2 is selectively lethal to MYC-dependent human breast cancer cells
    Kang, Jian
    Sergio, C. Marcelo
    Sutherland, Robert L.
    Musgrove, Elizabeth A.
    BMC CANCER, 2014, 14
  • [27] Targeting cyclin-dependent kinase 1 (CDK1) but not CDK4/6 or CDK2 is selectively lethal to MYC-dependent human breast cancer cells
    Jian Kang
    C Marcelo Sergio
    Robert L Sutherland
    Elizabeth A Musgrove
    BMC Cancer, 14
  • [28] Identification of Candidate Cyclin-dependent kinase 1 (Cdk1) Substrates in Mitosis by Quantitative Phosphoproteomics
    Petrone, Adam
    Adamo, Mark E.
    Cheng, Chao
    Kettenbach, Arminja N.
    MOLECULAR & CELLULAR PROTEOMICS, 2016, 15 (07) : 2448 - 2461
  • [29] Inhibition of cyclin-dependent kinase 1 (CDK1) by indirubin derivatives in human tumour cells
    D Marko
    S Schätzle
    A Friedel
    A Genzlinger
    H Zankl
    L Meijer
    G Eisenbrand
    British Journal of Cancer, 2001, 84 : 283 - 289
  • [30] Inhibition of cyclin-dependent kinase 1 (CDK1) by indirubin derivatives in human tumour cells
    Marko, D
    Schätzle, S
    Friedel, A
    Genzlinger, A
    Zankl, H
    Meijer, L
    Eisenbrand, G
    BRITISH JOURNAL OF CANCER, 2001, 84 (02) : 283 - 289
12345